-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, the NMPA official website showed that Nanjing Chia Tai Tianqing's lenvatinib was approved for listing, becoming the third domestic generic drug of this variety
Lenvatinib is an inhibitor of vascular endothelial growth factor receptor (VEGFR) 1 to 3, fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) α, RET and KIT inhibitors, ranking second in China A first-line targeted therapy drug for liver cancer
Statistics show that China is the country with the largest number of liver cancer patients in the world, with about 466,000 new cases each year, accounting for 55% of the world’s total; 422,000 deaths, accounting for 45%-50% of the world’s total
Based on clinical needs, lenvatinib's domestic sales continued to grow rapidly after approval
It is a pity that in the 2019 medical insurance negotiations, lenvatinib came back unfavorably, disappointing countless liver cancer patients; fortunately, in the 2020 medical insurance negotiations, the price of lenvatinib was reduced by 80% and successfully entered the medical insurance.
According to the Insight database, in addition to the approved products, there are currently nine other companies whose generic drugs for lenvatinib are reported to be on the market
Details of lenvatinib domestic competition
From the Insight database (http://db.
